Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of YR001 Topical Ointment in Healthy Chinese Participants
NCT07673458Phase 1Recruiting
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PA032 (4 arms), sponsored by Hangzhou Yirui Pharmaceutical Technology Co., Ltd. Primary endpoint: Incidence of Adverse Events up to 30 days. Started Jun 2026; status: recruiting.
02
Drugs
PA032
Beyond the preview
Go deeper on NCT07673458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673458.